Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development

  Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President,
  Research and Development

Business Wire

LEXINGTON, Mass. -- March 13, 2013

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of
Dr. Sumant Ramachandra as President, Research and Development.

Prior to Synta, Dr. Ramachandra was Senior Vice President, Research and
Development (R&D), Regulatory and Medical Affairs, and Chief Scientific
Officer of Hospira, a specialty pharmaceuticals and medical device company. At
Hospira, Dr. Ramachandra led a 1,200 person R&D organization and was
recognized for his achievements and contributions as a healthcare leader in
PharmaVoice’s “100 of the Most Inspiring People,” Diversity MBA’s “Top 100
Under 50 Diverse Executive Leaders,” and Chicago Business’ “Crain’s
40-under-40.”

Prior to joining Hospira in 2008, Dr. Ramachandra was Vice President and
oncology portfolio therapeutic area leader at Merck & Co. (formerly
Schering-Plough), and prior to Merck/Schering-Plough he was therapeutic area
head for medical oncology at Pfizer (formerly Pharmacia). At these companies,
Dr. Ramachandra drove the development, regulatory approval, and market
expansion studies for numerous oncology products.

“Sumant brings a broad range of development and regulatory leadership
experience, as well as a unique perspective having led both oncology
development at large pharmaceutical companies, and the broader range of R&D
functions at a large, global specialty pharma company,” said Safi Bahcall,
President and CEO, Synta. “Sumant’s experiences with a wide range of drugs,
manufacturers, pharma companies, payors, providers, and regulatory agencies
will enhance our ability to realize the full potential of our product pipeline
to benefit patients.”

“The programs at Synta can change the treatment of many types of cancers,”
said Dr. Ramachandra. “In addition, Synta’s culture of innovation,
collaboration, and commitment to speed and excellence in execution are
exciting and critical to success in our industry. I am very much looking
forward to being part of the Synta team and contributing to bringing these new
drugs to cancer patients.”

Dr. Ramachandra received a bachelor's degree in biochemistry from Rutgers
University, and M.D. and Ph.D. degrees from the University of Medicine and
Dentistry-New Jersey Medical School. He conducted his residency at the
Harvard-affiliated Massachusetts General Hospital (MGH). Dr. Ramachandra also
earned a master's of business administration from the Wharton Business School
at the University of Pennsylvania.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities. For more
information, please visit www.syntapharma.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified by the
use of forward-looking terminology such as "will", "would", "should",
"expects", "anticipates", "intends", "plans", "believes", "may", "estimates",
"predicts", "projects", or similar expressions intended to identify
forward-looking statements. Such statements, including statements relating to
the timing, developments and progress of our clinical and preclinical
programs, reflect our current views with respect to future events and are
based on assumptions and subject to risks and uncertainties that could cause
actual results to differ materially from those expressed or implied by such
forward-looking statements, including those described in "Risk Factors" of our
Form 10-K for the year ended December 31, 2011 as filed with the Securities
and Exchange Commission. Synta undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future events
or otherwise, except as required by law.

Contact:

Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213